Protalix BioTherapeutics (PLX) Exchange Rate Effect (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Exchange Rate Effect of -$77000.0 for Q1 2026, down 862.5% year-over-year from $10098.4 in Q1 2025, and down 148.39% quarter-over-quarter from -$31000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Exchange Rate Effect (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Exchange Rate Effect history runs 17 years deep, the most recent figure standing at -$77000.0 for Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 862.5% year-over-year to -$77000.0; the TTM figure through Mar 2026 stood at -$116000.0 (down 583.33% YoY), while the FY2025 annual figure was -$47000.0, down 288.0% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$77000.0, down from -$31000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $54000.0 in Q4 2024, with the low at -$77000.0 in Q1 2026.
- The 5-year median for Exchange Rate Effect is -$16000.0 (2024), against an average of -$18125.0.
- The sharpest annual moves came in 2022 and 2024: Exchange Rate Effect slumped 900.0% in 2022, then soared 300.0% in 2024.
- Protalix BioTherapeutics' Exchange Rate Effect stood at -$26000.0 in 2022, then decreased by 3.85% to -$27000.0 in 2023, then jumped by 300.0% to $54000.0 in 2024, then slumped by 157.41% to -$31000.0 in 2025, then sank by 148.39% to -$77000.0 in 2026.
- Business Quant data shows PLX's Exchange Rate Effect at -$77000.0 in Q1 2026, -$31000.0 in Q4 2025, and -$12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -2.45 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -287,000.00 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.63 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 454,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 454,000.00 |
| Jun 30, 2026 | 454,000.00 |
| Mar 31, 2026 | -77,000.00 |
| Mar 31, 2026 | -77,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |